Phase 2 Parkinson's disease trials recruiting now

All Parkinson's disease trials, every phase

Other phases for Parkinson's disease

Phase 2 Parkinson's disease trials

• A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's Disease
  NCT07809438 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
  NCT06753331 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 72 Years · Sex: All (male and female) · 2 locations
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 72 locations
• A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
  NCT07322887 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
  NCT06285643 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: All (male and female) · 46 locations
• A Study of Buntanetap in Participants With PD
  NCT07284784 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 85 Years · Sex: All (male and female) · 27 locations
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
  NCT06976268 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 22 locations
• A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
  NCT07432958 · Phase: Phase 2 · Ages: 30 Years to 80 Years · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
  NCT07804615 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 30 locations
• A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease
  NCT07157735 · Phase: Phase 2 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
  NCT07166757 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
  NCT05824728 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · 1 location
• D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
  NCT07312110 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 11 locations
• Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
  NCT07265596 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Etoricoxib in Patients With Parkinsonian Disease
  NCT07370532 · Phase: Phase 2 · Ages: 50 Years to 70 Years · Sex: All (male and female) · 1 location
• Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
  NCT07020026 · Phase: Phase 2 · Ages: 45 Years to 85 Years · Sex: All (male and female) · 1 location
• Fexofenadine as Adjuvant Therapy in Parkinson Disease
  NCT06785298 · Phase: Phase 2, Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female) · 1 location
• Imaging Depression in Parkinson's Disease
  NCT06402955 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
  NCT05266417 · Phase: Phase 2 · Ages: 30 Years and older · Sex: All (male and female) · 4 locations
• Ketamine for Veterans With Parkinson's Disease
  NCT06231563 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
  NCT07005180 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 5 locations
• Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS
  NCT07442747 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
  NCT07154511 · Phase: Phase 1, Phase 2 · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease
  NCT05568498 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• Psilocybin Therapy for Depression in Parkinson's Disease
  NCT06455293 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• Rehabilitation of Airway Protection in Parkinson's Disease
  NCT05700825 · Phase: Phase 2 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 2 locations
• Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
  NCT07001150 · Phase: Phase 2 · Ages: 45 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
  NCT07461220 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 14 locations
• Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
  NCT05395624 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 9 locations
• Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
  NCT07142044 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
  NCT04691661 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 7 locations
• Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease
  NCT06798844 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• Tenapanor in Synucleinopathy-Related Constipation
  NCT06460038 · Phase: Phase 2 · Ages: 50 Years to 89 Years · Sex: All (male and female) · 1 location
• The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
  NCT07610369 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
  NCT06167681 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 75 Years · Sex: All (male and female) · 2 locations
• The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
  NCT07156773 · Phase: Phase 2 · Ages: 30 Years to 85 Years · Sex: All (male and female) · 1 location
• The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
  NCT03457493 · Phase: Phase 1, Phase 2 · Ages: 30 Years and older · Sex: All (male and female) · 1 location
• This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
  NCT07102342 · Phase: Phase 1, Phase 2 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location
• Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease
  NCT04643327 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
  NCT07725562 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
  NCT07182058 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
  NCT06120049 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 4 locations
• rTMS to Improve Cognition in Parkinson's
  NCT03836950 · Phase: Phase 1, Phase 2 · Ages: 50 Years and older · Sex: All (male and female) · 2 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.